Vaccine (mRNA vaccine) · Immune activation, directed at patient-specific tumor-associated antigens · developed by BioNTech
Autogene cevumeran is an individualized mRNA-based therapeutic cancer vaccine encoding tumor-associated antigens specific to each patient's cancer. Antigen-presenting cells take up and translate the mRNA, presenting the antigens on MHC molecules to induce cytotoxic T-lymphocyte and memory T-cell responses. It is studied in colorectal cancer (stage II and III) and pancreatic ductal adenocarcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05968326 | Phase 2 | Adenocarcinoma, Pancreatic Ductal | Active not recruiting | BNTX |
| NCT04486378 | Phase 2 | Colorectal Cancer Stage II | Active not recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adenocarcinoma, Pancreatic DuctalColorectal Cancer Stage IIColorectal Cancer Stage III
Updated Nov 15, 2026. Something wrong or missing? Report it on the BNTX page.
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →